ST. PAUL, Minn. , Oct.
29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH ), today announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant. Luminary's G-Rex® Grant will enable expeditious process development and IND-enabling studies of several novel CAR γδ T cell therapies that will be evaluated in Phase 1 clinical trials for the treatment of various autoimmune conditions. Luminary Therapeutics' CAR γδ T cell drug products contain a combination of the Vδ1 and Vδ2 subsets, a distinct approach from other developers of γδ T cell therapies, which Luminary anticipates providing improved cytotoxicity, greater adaptive capacity, and increased persistence.
Luminary's technology also employs an "immune cloaking" mechanism to assist the γδ T cells in evading the host's immune system by reducing the expression of MHC class I/II on the surface of the γδ T cells. Finally, Luminary Therapeutics deploys Bio-Techne's novel transposition-based gene engineering technology called TcBusterTM which has fundamental advantages in the reduction of time and cost associated with clinical translation of a cell therapy drug product. Luminary has previously presented cost analysis indicating that their CAR γδ T cell therapies can yield 180-200 patient doses per manufacturing run at a manufacturing cost of less than $10,000 per drug product.
"Luminary is very grateful to be a beneficiary of the.
